Corvus rises as it invests in China partner to advance skin, asthma drug trials

Corvus Pharmaceuticals

09/06/2026 12:40

** Shares of biotech firm Corvus Pharmaceuticals CRVS.O rise 2% to $11.36 premarket
** Co invests $5 mln in Angel Pharma to support trials of soquelitinib for atopic dermatitis, a chronic skin disease causing inflammation and itching - CRVS
** Funding to also back planned asthma study; skin trial readout expected late 2026, asthma study to start early 2027, co says
** Angel Pharma, 49% owned by Corvus, is enrolling patients in China study, testing multiple doses over 12 weeks - CRVS
** Co says drug also under study in U.S. for blood cancers and skin condition
** Says investment expands exposure to China’s inflammation and immunology market
** As of last close, stock up ~45% YTD
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))